 Etoposide
"Etoposide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
| Descriptor ID |
D005047
|
| MeSH Number(s) |
D02.455.426.559.847.638.960.675.250 D04.615.638.960.675.250 D09.408.348.275
|
| Concept/Terms |
Etoposide- Etoposide
- Eposide
- Demethyl Epipodophyllotoxin Ethylidine Glucoside
Etopos- Etopos
- Lemery Brand of Etoposide
Exitop- Exitop
- Baxter Oncology Brand of Etoposide
Lastet- Lastet
- Sanfer Brand of Etoposide
- Prasfarma Brand of Etoposide
Onkoposid- Onkoposid
- Onkoworks Brand of Etoposide
Riboposid- Riboposid
- ribosepharm Brand of Etoposide
Toposar- Toposar
- Teva Brand of Etoposide
- Etoposide Teva
Vepesid- Vepesid
- Bristol-Myers Squibb Brand of Etoposide
- Bristol Myers Squibb Brand of Etoposide
- Bristol-Myers Brand of Etoposide
- Bristol Myers Brand of Etoposide
Celltop- Celltop
- Baxter Brand of Etoposide
Eposin- Eposin
- Tedec Meiji Brand of Etoposide
- Pharmachemie Brand of Etoposide
- Etomedac
- Medac Brand of Etoposide
Eto-GRY- Eto-GRY
- Eto GRY
- Gry Brand of Etoposide
|
Below are MeSH descriptors whose meaning is more general than "Etoposide".
Below are MeSH descriptors whose meaning is more specific than "Etoposide".
This graph shows the total number of publications written about "Etoposide" by people in this website by year, and whether "Etoposide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2019 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Etoposide" by people in Profiles.
-
Elsayed AH, Cao X, Mitra AK, Wu H, Raimondi S, Cogle C, Al-Mansour Z, Ribeiro RC, Gamis A, Kolb EA, Aplenc R, Alonzo TA, Meshinchi S, Rubnitz J, Pounds S, Lamba JK. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. J Clin Oncol. 2022 03 01; 40(7):772-783.
-
Tillman EM, Suppes SL, Miles N, Duty AM, Kelley KL, Goldman JL. Risks and mitigation strategies to prevent etoposide infusion-related reactions in children. Pharmacotherapy. 2021 08; 41(8):700-706.
-
Welch D, Kahen E, Fridley B, Brohl AS, Cubitt CL, Reed DR. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines. PLoS One. 2019; 14(9):e0222228.
-
Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Jul; 62(7):1184-9.
-
Zaky W, Dhall G, Khatua S, Brown RJ, Ginn KF, Gardner SL, Yildiz VO, Yankelevich M, Finlay JL. Choroid plexus carcinoma in children: the Head Start experience. Pediatr Blood Cancer. 2015 May; 62(5):784-9.
-
Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60.
-
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2012 Nov; 97(11):1770-3.
-
Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 2012 Oct 01; 118(19):4806-14.
-
Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012 Feb 01; 118(3):761-9.
-
Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003 Aug 01; 21(15):2940-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|